FAME 2 Study: Five-Year Outcomes with PCI Guided by Fractional Flow Reserve
Presented during EuroPCR 2018, the final 5-year FAME 2 analysis shows continued benefit for percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) over medical therapy in stable coronary artery disease (CAD), but also a new signal for fewer myocardial infarctions (MIs) among those treated with stents.
EVOLVE II & SENIOR Trial Data Continues to Impress. Prof Meredith discusses the results
The collective body of clinical evidence continues to demonstrate best-in-class healing with the SYNERGY™ BP Stent. Watch Prof. Ian Meredith, EVP and Global Chief Medical Officer for Boston Scientific, and other global KOLs discuss the 4-year results of the EVOLVE II Trial and recent evidence on short DAPT from the SENIOR Trial.